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doi:10.10Abstract: The antinociceptive profile of St. John’s Wort (SJW) was investigated in mice in a condition
of acute thermal and chemical pain, together with the mechanism that might underlie this effect. A
dried extract of SJW induced a prolonged antinociception that persisted for 120 minutes after admin-
istration. The thermal antinociception was prevented by naloxone and by the protein kinase C (PKC)
activator PMA, whereas the chemical antinociception was prevented by PMA, remaining naloxone
insensitive. A chloroform (CHL) and a methanol (MET) fraction, obtained to investigate the involve-
ment of the SJW main components, hyperforin and hypericin/flavonoid, respectively, increased pain
threshold with a time course comparable to the dried extract. The CHL antinociception was prevented
by naloxone, whereas the MET antinociception was antagonized by PMA. Purified hyperforin and
hypericin showed an antinociceptive efficacy comparable to CHL and MET, respectively. Conversely,
flavonoids were devoid of any effect. The administration of yohimbine and atropine did not modify
SJW, CHL and MET antinociception. These results indicate that both CHL and MET fractions mediate
the SJW-induced antinociception. In particular, the presence of hypericin was fundamental to induce
both thermal and chemical antinociception through the inhibition of the PKC activity, whereas hyper-
forin selectively produced a thermal opioid antinociception.
Perspective: This article presents evidence of a persistent thermal and chemical antinociception of
SJW that is mainly mediated by PKC-inhibiting mechanisms. These findings identify important targets
for a longer-acting activation of endogenous pain systems and should potentially help clinicians who
seek safe, tolerable, and prolonged treatments for pain relief.
ª 2010 by the American Pain Society
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Wort (SJW), is a herbaceous perennial plant long
known for its putative medicinal properties. It
has been used, topically, in popular medicine since an-
cient times for the treatment of skin wounds, eczema,
burns and inflammation.2,6 In 1525, the Swiss physician
Paracelsus established its use for the treatment of psychi-
atric disorders; since then, it has been used in traditional
European medicine to treat neuralgia, anxiety, neurosis,
and depression.5 Although clinical trials have given con-February 10, 2009; Revised May 18, 2009; Accepted June 24,
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16/j.jpain.2009.06.013tradictory results, alcoholic extracts of SJW are presently
used mainly for the treatment of mild-to-moderate
forms of depression as an alternative to classic antide-
pressants, with a favorable side-effect profile.21
The most common SJW preparations used are hydroal-
coholic extracts of the aerial portion of the plant. These
contain at least 10 different kinds of biochemical
compounds: flavonoids (including rutin, hyperoside,
quercetin, and quercitrin), naphtodianthrones (includ-
ing hypericin and pseudohypericin), acylphloroglucinols
(including hyperforin and adhyperforin), proanthocyani-
dins, procyanidines, tannins, essential oils, amino acids,
phenylpropanes, xantones, and other hydrosoluble com-
pounds (organic acids, peptides, and polysaccharides).15
The first 3 groups are the most abundant ones and the
agents mainly responsible for the described traditional
use of the herbaceous plant. Hypericin and hyperforin
have been isolated in only a few other plants. Total149
150 St John Wort’s Antinociceptionhypericins usually amount to about .3% of hydroalco-
holic extracts and are the most potent natural photosen-
sitizers so far described, with potent application for
antitumoral photodynamic therapy.1 Attention has re-
cently increasingly been paid to hyperforin (1–5% in
the SJW extract) as the main active component with
antidepressant effect, but also endowed with other
pharmacological effects including antinflammatory and
proinflammatory effects, antibacterial, antitumoral,
and antiangiogenetic properties.23 Flavonoids account
for about 2 to 4% of the hydroalcoholic extract with
a wide distribution in many plants.
Pharmacological studies on SJW have focused mainly
on its antidepressant activity. However, some studies
have documented other bioactivities produced by this
herbal plant. In particular, its anti-inflammatory activity
following not only topical,30 but also systemic, adminis-
tration has been examined.22 SJW inhibits some events
involved in the inflammatory reaction such as the expres-
sion of cyclo-oxygenase-2,22 prostaglandin E2,17 induc-
ible nitric-oxide synthase,34 and interleukin 6.12
These reports hypothesize a role of SJW in the modula-
tion of pain perception, supported by a recent paper that
indicates the antinociceptive effect of high SJW concen-
trations in the formalin test.35 Thus, the aim of this study
was to characterize the antinociceptive profile of SJW
with the mechanism that might underlie this effect in
a condition of acute thermal (hot-plate test) and chemi-
cal (abdominal-constriction test) pain. The role of the
SJW main components—hypericin, hyperforin, and fla-
vonoids—in the modulation of the pain threshold was
also investigated since, at present, very little is known
on this aspect.Methods
Animals
Male Swiss albino mice (24–26 g) from Morini (San Polo
d’Enza, Italy) were used. Ten mice were housed per cage.
The cages were placed in the experimental room 24
hours before the test for acclimatization. The animals
were fed a standard laboratory diet and tap water ad
libitum and kept at 236 1C with a 12-hour light/dark cy-
cle, with light at 7 am. All experiments were carried out
in accordance with the NIH Guide for the Care and Use of
Laboratory animals. All efforts were made to minimize
animal suffering, and to reduce the number of animals
used.Hot-Plate Test
The hot-plate test was performed as previously de-
scribed.13 Mice were placed inside a stainless-steel con-
tainer, which was set thermostatically at 52.5 6 .1C in
a precision water bath (KW Mechanical Workshop, Siena,
Italy). Reaction times (in seconds) were measured with
a stopwatch before and 30, 60, 90, 120, 150 and 180 min-
utes after administration of the drug . The endpoint used
was the licking of the fore or hind paws. Those mice scor-
ing less than 12 and more than 18 seconds in the pretestwere rejected (30%). An arbitrary cutoff time of 45
seconds was adopted. 12 mice per group were used.Abdominal-Constriction Test
Mice were intraperitoneally (ip) injected with a .6%
solution of acetic acid (10 mL kg1). The number of
stretching movements was counted for 10 minutes, start-
ing 5 minutes after acetic acid injection. 12 mice per
group were used.Rota-Rod Test
The apparatus consisted of a base platform and a rotat-
ing rod with a diameter of 3 cm and a nonslippery sur-
face. The rod was placed at a height of 15 cm from the
base. The rod, 30 cm in length, was divided into 5 equal
sections by 6 disks. Thus, up to 5 mice were tested simul-
taneously on the apparatus, with a rod-rotating speed of
16 rpm. The integrity of motor coordination was assessed
on the basis of the number of falls from the rod in 30 sec-
onds. Those mice scoring less than 3 and more than 6 falls
in the pretest were rejected (20%). The number of falls
was measured before (pretest) and 60, 90, and 120 min
after administration of SJW, CHL and MET. 10 mice per
group were used.Hole-Board Test
The hole board test consisted of a 40-cm square plane
with 16 flush-mounted cylindrical holes (3 cm diameter)
distributed 4 by 4 in an equidistant, grid-like manner.
Mice were placed on the center of the board 1 by 1
and allowed to move about freely for a period of 5 min-
utes each. Two photobeams, crossing the plane from
midpoint to mid point of opposite sides, thus dividing
the plane into 4 equal quadrants, automatically signaled
the movement of the animal (counts in 5 minutes) on the
surface of the plane (spontaneous motility). Miniature
photoelectric cells, in each of the 16 holes, recorded
(counts in 5 minutes) the exploration of the holes (ex-
ploratory activity) by the mice. The test was performed
90 minutes after administration of SJW, CHL and MET.
10 mice per group were used.Icv Injection Technique
Icv administration was performed under ether anaes-
thesia with isotonic saline as solvent as previously de-
scribed.13 During anaesthesia, mice were grasped firmly
by the loose skin behind the head. A hypodermic needle
(.4 mm external diameter) attached to a 10-mL syringe was
inserted perpendicularly through the skull and no more
than 2 mm into the brain of the mouse, where a 5-mL so-
lution was then administered. The injection site was 1
mm to the right or left from the midpoint on a line drawn
through to the anterior base of the ears. Injections were
performed randomly into the right or left ventricle. To
ascertain that solutions were administered exactly into
the cerebral ventricle, some mice were injected with
5 mL of diluted 1:10 India ink and their brains were exam-
ined macroscopically after sectioning. The accuracy of
Galeotti et al 151the injection technique was evaluated with 95% of
injections being correct.HPLC-DAD and HPLC-MS Drug Analyses
To evaluate the constituents’ content, an HPLC analysis
was performed using a method described in the litera-
ture,7 modified for our experimental necessities. The
identification of the constituents was performed using
combined HPLC-diode array detection (DAD) analysis
and HPLC-thermospray mass spectrometry. The quantifi-
cation of the constituents was performed using rutin as
an external standard and consideration of each constitu-
ent and the relative response factor (RRF) with respect to
the rutin, as previously reported.7 All the samples were
analyzed in triplicate and a calibration graph with 6
data points of external standard was used.
The detection limit (LoD) and the quantitatiton limit
(LoQ) for rutin was determined by calculation of the sig-
nal-to-noise ratio. A 3:1 signal-to-noise ratio is generally
considered acceptable for estimating the detection limit.
The sample that produces a signal-to-noise ratio of
approximately 10:1 corresponds to the concentration at
which the analyte can be reliably quantified. The LoQ
resulted in 15 ng and the LoD was 6 ng.
The HPLC system consisted of an HP 1100L instrument
with a diode array detector and managed by an HP
Chem workstation (Agilent Technologies, Palo Alto,
CA). The reverse-phase column was a 201 TP 54 (5 ı`m,
250 mm, .5 mm id, 300 A; Vydac Separation Group, Hes-
peria, CA) maintained at 26C. The mobile phase was
a 5-step linear solvent gradient CH3CN/CH3OH/H2O (pH
3.2, HCOOH) over a 60-minute period at a flow rate of
1 mL/minute, previously reported in the literature.3 The
injected volume of sample was a 20-mL solution. UV–vis
spectra were recorded in the range 200 to 590 nm, and
chromatograms were acquired at 230, 254, 270, 350,
and 590 nm.
The HPLC system was interfaced with an HP 1100 MSD
APIelectrospray (Agilent Technologies). The interface
geometry, with an orthogonal position of the nebulizer
with respect to the capillary inlet, allowed the use of
analytical conditions similar to those of the HPLC-DAD
analysis. The same column, mobile phase, time period,
and flow rate were used.
Mass spectrometry operating conditions were opti-
mized in order to achieve maximum sensitivity values:
gas temperature 350C at a flow rate of 10 L/minute; neb-
ulizer pressure 30 psi; quadrupole temperature 30C; and
capillary voltage 3,500 V. Full-scan spectra from m/z 100
to 800 in the positive ion mode were obtained (scan
time 1 second).Preparation of Chloroform andMethanol
Fractions
A solution of dried extract (1 g) in 10 mL of chloroform
was stirred for 3 hours in the dark. The mixture was
filtered and the solution was evaporated to obtain a
residue of 200 mg, containing the pholoroglucinols as
confirmed by HPLC-DAD-ESI-MS analysis.The residue present on the filter was washed with 10
mL of methanol. The methanol solution was evaporated
and a residue of 700 mg was obtained. The HPLC-DAD-
ESI-MS analysis showed in this fraction only the presence
of flavonoids and naphtodianthrones.Drugs
Indena Research Laboratories (Settala, Milan, Italy)
offered a commercial sample of Hypericum perforatum
dried extract –Lotto 28662/M1–B.A. 84204 and kindly
provided the reference rutin trihydrate (batch no.
K12408717, standard purity 96.25% considering the
content of residual solvents, moisture and amount of
impurities).
The following drugs were used: naloxone hydro-
chloride, atropine sulfate, yohimbine hydrochloride,
benzyliden-naltrexone (BNTX), nor-binaltorphimine
dihydrochloride (nor-BNI), D-Phe-Cys-Tyr-D-Trp-Orn-Thr-
Pen-Thr-NH2 (CTOP), hypericin, hyperforin, hyperoside,
quercetin (Sigma, Milan, Italy); phorbol-12-myristate-
13-acetate (PMA), (Calbiochem, Milan, Italy); D- amphet-
amine (De Angeli, Rome, Italy), carboxymethylcellulose
sodium salt, (CMC) (Fluka Chemie GmbH, Steinheim,
Germany). Other chemicals were of the highest quality
commercially available.
SJW dried extract, chloroform fraction (CHL), metha-
nol fraction (MET), hypericin, hyperforin, quercetin,
and hyperoside were dissolved in a 1% CMC solution im-
mediately before use and administered by gavage. All
other drugs were dissolved in isotonic (NaCl .9%) saline
solution immediately before use. Drug concentrations
were prepared so that the necessary dose could be ad-
ministered in a volume of 10 mL kg1 by intraperitoneal
(ip), subcutaneous (sc), per os (po) injection, or in a vol-
ume of 5 mL by intracerebroventricular (icv) injection.Drug Administration
SJW dried extract, CHL and MET fractions, hypericin,
hyperforin, quercetin and hyperoside were administered
90 minutes before the hot-plate and abdominal-constric-
tion tests, in correspondence to their maximum effect as
determined by time-course experiments.
Hot plate hypericin .12 mg kg,1 hyperforin 1.956 mg
kg,1 quercetin .498 mg kg,1 and hyperoside 3.81 mg
kg1 were orally administered 90 minutes before the
test. These doses correspond to the percentages present
in a 60 mg kg1-preparation of SJW dried extract. CHL
and MET fractions were administered in a concentration
containing the above-mentioned content of their main
components, hyperforin and hypericin, respectively.
Abdominal constriction test: hypericin .06 mg kg,1
hyperforin .978 mg kg,1 quercetin .249 mg kg,1
and hyperoside 1.905 mg kg1 were orally administered
90 minutes before the test. These doses correspond to
the percentages present in a 30 mg kg1-preparation
of SJW dried extract. CHL and MET fractions were
administered in a concentration containing the
above-mentioned content of their main components,
hyperforin and hypericin, respectively.
152 St John Wort’s AntinociceptionNaloxone (1 mg kg1 ip), atropine (5 mg k1 ip),
yohimbine (3 mg kg1 ip), CTOP (.5 mg per mouse icv),
naltriben (19 mg per mouse icv), BNTX (35 mg per mouse
icv), nor-BNI (.735mg per mouse icv) were injected 70 min-
utes after SJW, CHL or METadministration. PMA (15 pmol
per mouse icv) was injected 30 minutes after SJW, CHL or
MET administration. D-amphetamine (2 mg kg1 sc), was
administered 15 minutes before the hole-board test.
Doses and administration schedule were chosen on the
basis of time-course and dose-response experiments
previously performed in our laboratory.Statistical Analysis
All experimental results are given as the mean6S.E.M.
An analysis of variance ANOVA, followed by Fisher’s
Protected Least Significant Difference procedure for
post hoc comparison, were used to verify significance
between 2 means. P values of less than .05 were
considered significant.Results
The main components of SJW dried extract were flavo-
noids (12.72%), phloroglucinols (4.23%) and naphto-
dianthrones (0.32%), as reported in Table 1. In order to
investigate the role of these components in the mecha-
nism of action of SJW, a chloroform and a methanol
fraction were obtained from the dried extract. The
chloroform fraction (CHL) contained phloroglucinols
whereas the methanol fraction (MET) showed the pres-Table 1. Composition of the SJW Dried Extract,
CHL, and MET Fractions
CONTENT % (MG/100 MG)
CONSTITUENT SJW CHL MET
Flavonoids
Rutin 4.28
Hyperoside 6.35
Isoquercitrin 0.61
Rutin, Hyperoside,
Isoquercitrin
n.d. 9.29
Quercitrin 0.65 n.d. 0.69
Quercetin 0.83 n.d. 0.42
I3, II8-Biapigenin 0.62 0.29 0.25
Total flavonoids 12.72
Phloroglucinols
Oxihyperforin 1.16 n.d.
Furohyperforin 1.21 n.d.
Hyperforin 12.49 n.d.
Adhyperforin 1.34 n.d.
Total Phloroglucinols 4.23
Naphtodianthrones
Pseudohypericin 0.04 0.11
Hypericin 0.01 0.20
Total
naphtodianthrones
0.32
Abbreviations: SJW, St. John’s Wort; CHL, chloroform fraction; MET, methanol
fraction.
NOTE. The content of each constituent is expressed as percentage (mg/100 mg).ence of naphtodiantrones and flavonoids representing
a hypericin and flavonoid rich fraction (Table 1).
Fig 1 shows the HPLC profiles ofHypericumperforatum
L. dried extract, at 270 nm (Fig 1A) and 590 nm (Fig 1B).
A dried extract of SJW showed a dose-dependent (1 to
100 mg kg1 po) antinociceptive activity against a ther-
mal stimulus in the mouse hot-plate test. The dose of
1 mg kg1 po was devoid of any effect. At 10 mg kg1
po, SJW significantly increased the mouse pain thresh-
old. The antinociceptive effect peaked at 60 mg kg1
po and then it diminished (Fig 2A). SJW 1000 mg kg1
was ineffective. Time-course experiments showed that
SJW antinociception (10 and 60 mg kg1 po) became sta-
tistically significant 60 minutes after oral administration
and peaked at 90 minutes. Then it slowly diminished,
disappearing at 180 minutes (Fig 2B).
Both chloroform fraction (CHL) and methanol fraction
(MET) showed antinociceptive properties when adminis-
tered in a concentration corresponding to the content of
their main antinociceptive components, hyperforin and
hypericin, respectively, present in a 60 mg kg1 prepara-
tion of SJW dried extract (F3,44(5,177) P < .001) (Fig 3A).
Time-course experiments showed that CHL and
METantinociception were endowed with the same phar-
macological profile of SJW dried extract. Their antinoci-
ceptive effect became statistically significant 60 minutes
after oral administration, peaked at 90 minutes, and
slowly diminished, disappearing at 180 minutes (Fig 3B).
Hyperforin (HYF), when administered alone, produced
an antinociceptive effect of intensity comparable to CHL
fraction (Fig 3C). Similarly, hypericin (HYR) increased the
pain threshold to a value comparable to that obtained in
the MET group. Neither quercetin (QUER) or hyperoside
(HYS) showed antinociceptive properties or increased hy-
pericin-induced antinociception (F8 ,99(6,948) P < .001)
(Fig 3C).
SJW dried extract antinociception (60 mg kg1 po) was
prevented by the opioid antagonist naloxone (1 mg kg1
ip) and by the administration of the PKC activator PMA
(15 pmol per mouse icv), as illustrated in Fig 4A. Pretreat-
ment with atropine (5 mg kg1 ip) or yohimbine (3 mg
kg1 ip) was devoid of any effect (F5,66(6,560)
P <.0001) (Fig 4A).
The increase of pain threshold produced by CHL,
administered at a concentration corresponding to the
hyperforin content of a 60 mg kg1 po SJW dried extract
preparation, was selectively antagonized by naloxone
pretreatment (F5 ,66(5 ,903) P< .0001) (Fig 4B), whereas
MET (corresponding to the hypericin content present in
60 mg kg1 preparation of SJW dried extract) was selec-
tively prevented by PMA (F5 ,66(5,479) P < .0001) (Fig 4C).
Pretreatment with atropine (5 mg kg1 ip) or yohimbine
(3 mg kg1 ip) was devoid of any effect against both SJW
fractions (Figs 4B, 4C).
The increase of pain threshold produced by SJW dried
extract was prevented by the m-opioid selective antago-
nist CTOP, the k-opioid selective antagonist nor-BNI, the
d1 antagonist BNTX, and the d2 antagonist naltriben
(Fig 5A), indicating the lack of selectivity among the
opioid receptor subtypes (F5,66(5,915) P <.001). CHL
produced similar results (F5,66(5,726) P < .001) (Fig 5B).
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Figure 1. HPLC profiles of Hypericum perforatum L. extract. (A): HPLC profile at 270 nm. Rutin was linear from 4.5 to 100 mg/mL and
all the curves had coefficient of linear correlation$.999 with y-intercepts which were close to zero. tR = 16.43 minutes, rutin, tR = 16.77
min., hyperoside, tR = 17.17 minutes, isoquercitrin, tR = 18.74 minutes, quercitrin, tR = 29.07 minutes, quercetin, tR = 36.32 minutes, I3,
II8-biapigenin, tR = 44.73 minutes, furohyperforin, tR = 45.47 minutes, hyperforin, tR = 45.94 minutes, adhyperforin. (B):HPLC profile at
590 nm. tR = 38.18 minutes, pseudohypericin, tR = 40.27 minutes, hypericin.
Galeotti et al 153All the pharmacological antagonists as well as the PKC
activator PMA, at the concentrations administered, were
devoid of any antinociceptive/hypernociceptive effect,
as previously demonstrated by us.13
Oral administration of SJW dried extract caused a sig-
nificant inhibition on the writhing response induced by
intraperitoneal injection of a .6% acetic acid solution
when compared with CMC-treated mice used as control
group. This effect became significant at 10 mg kg1 po,
peaked at 30 mg kg1 po, and disappeared at higher con-
centration (F5,66(8,103) P < .0001) (Fig 6A). Time- course
experiments showed that SJW antinociception became
statistically significant 60 minutes after oral
administration, peaked at 90 minutes, and was still sig-
nificant at 120 minutes. Then it slowly diminished, disap-
pearing at 180 minutes (data not shown).
Both MET and CHL reduced the number of abdominal
constrictions showing antinociceptive properties. MET
appeared to be the most effective fraction, being active
at 10 and 30 mg kg-1 po. CHL was less effective than MET,
reaching statistical significance only at 30 mg kg-1 po
(F8,99(3,977) P < .001) (Fig 6B).
Hypericin (HYR) reduced the number of abdominal
constrictions with the same intensity observed in
the MET group. Neither Quercetin (QUER) nor hypero-
side (HYS) showed antinociceptive properties or poten-
tated hypericin-induced antinociception (F6,77(4,914)
P < .001) (Fig. 6C).TheeffectofnaloxoneandPMAontheSJWdriedextract,
CHL, and MET fraction antinociception in the abdominal-
constriction test was examined. Naloxone did not modify
the effect produced by SJW dried extract and MET fraction,
whereas the antinociceptive effect induced by the CHL frac-
tion was slightly attenuated by naloxone (F7,88(10,923)
P < .0001) (Fig 7A). Conversely, PMA antagonized both
SJW- and MET-induced antinociception. In the same exper-
imental conditions, PMA did not influence CHL-induced
antinociceptive effect (F7,88(7,713) P < .0001) (Fig 7B). Nal-
oxone and PMA, when administered alone, did not modify
the number of abdominal constrictions in comparison to
the control group (Fig 7A,B).
The SJW dried extract, CHL, and MET fractions were
tested at the highest effective doses in order to assess
their effect on mouse locomotor behavior. Mice pre-
treated with the above-mentioned extracts at the dose
of 60 mg kg1 po were evaluated for motor coordination
by use of the rota-rod test, and for spontaneous mobility
and inspection activity by use of the hole-board test. The
spontaneous mobility (Fig 8A) as well as the inspection
activity (Fig 8B) of mice, expressed as counts in 5 minutes,
were unmodified by pretreatment with SJW dried
extract, CHL, and MET fractions in comparison with the
control group (CMC). D-amphetamine (2 mg kg1 sc),
used as positive control, significantly increased both
spontaneous mobility (F4 ,45(4 .343) P < .05) and explor-
atory activity (F4,45(3.998) P < .05) (Figs 8A, 8B). The
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Figure 3. Antinociceptive profile of St. John’s Wort (SJW) com-
ponents in the hot-plate test. (A): antinociceptive effect of SJW
dried extract (60 mg/kg po), chloroform (CHL) and methanol
(MET) fractions. Vertical lines represent s.e.m.; *P < .05 in com-
parison with carboxymethylcellulose (CMC) group. xP < .05 in
comparison with SJW-treated animals. (B): time-course curves
of CHL and MET fractions (1–10–60 mg/kg po). Vertical lines rep-
resent s.e.m.; *P < .05 in comparison with CMC group. (C): com-
parison between CHL and MET fraction antinociception and
their main components hyperforin (HYF), hypericin (HYR), quer-
cetin (QUER), and hyperoside (HYS). Vertical lines represent
s.e.m.; *P < .05 in comparison with CMC group.
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Figure 2. Antinociceptive effect of St. John’s Wort (SJW) dried
extract in the hot-plate test. (A): dose-response curve of SJW
dried extract (1–100 mg/kg po). Vertical lines represent s.e.m.;
*P < .05 in comparison with carboxymethylcellulose (CMC)
group. (B): time-course curves of SJW-dried extract (1–10–60
mg/kg po). Vertical lines represent s.e.m.; *P < .05 in comparison
with CMC group.
154 St John Wort’s Antinociceptionnumber of falls from the rotating rod, evaluated before
and 60, 90 and 120 minutes after treatment, showed the
lack of any impairment in the mouse motor coordination
by SJW dried extract and fractions administration in
comparison with the CMC group (Fig 8C).Discussion
An SJW dried extract, CHL, and MET fractions, given by
oral route, induced thermal and chemical antinocicep-
tion by increasing the licking latency values in the
hot-plate test, and by inhibiting acetic acid-induced ab-
dominal constrictions, respectively.
SJW dried extract produced a long-lasting increase of
the thermal-pain threshold, which appeared 60 minutes
after administration and was still detectable at 120 min-
utes. A recent study reported that an SJW extract was de-
void of any antinociceptive effect in the mouse tail-flick
test.35 This discrepancy might be explained by consider-
ing that the SJW-induced antinociception is endowed
with a bell-shaped trend. The authors looked for anincrease in the pain threshold at a concentration about
15 times higher than the effective ones. As demonstrated
by dose-response experiments, at this dose SJW is devoid
of any antinociceptive activity.
SJW dried extract also attenuated the nociceptive
response induced by intraperitoneal administration of
an acetic acid solution, producing a long-lasting antino-
ciception. A bell-shaped trend was observed also against
chemical nociception. Acetic acid causes algesia by liber-
ating endogenous mediators that excite pain nerve end-
ings, and is a sensitive method to investigate peripheral
and central antinociceptive efficacy of agents.10 The
SJW antinociceptive effect in the abdominal-constriction
test peaked at a concentration lower than that needed
to produce the maximal activity against a thermal stimu-
lus. It was not surprising since it is widely considered that
Figure 5. Prevention by CTOP, Nor-BNI, naltriben (NALTR) and
BNTX of thermal antinociception of St. John’s Wort (SJW) dried
extract (A), and chloroform (CHL) (B) fraction in the mouse hot-
plate test. The licking latency values were recorded 90 minutes
after SJW (60 mg kg1 po) and CHL (60 mg kg1 po) administra-
tion. Vertical lines represent s.e.m.; *P < .01 in comparison
with control group (CMC-treated mice); ^P < .05 in comparison
with corresponding antinociceptive compound-treated mice.Figure 4. Mechanism of thermal antinociception of St. John’s
Wort (SJW) dried extract, chloroform (CHL), and methanol
(MET) fractions. Effect produced by naloxone, yohimbine, atro-
pine and PMA on SJW dried extract (60 mg kg1 po) (A), CHL
(60 mg kg1 po) (B), and MET (60 mg kg1 po) (C) fractions in
the mouse hot-plate test. The licking latency values were re-
corded 90 minutes after SJW, CHL and MET administration. Ver-
tical lines represent s.e.m.; *P < .01 in comparison with control
group (CMC-treated mice); ^P < .05 in comparison with corre-
sponding antinociceptive compound-treated mice.
Galeotti et al 155analgesic effectiveness depends on the nociceptive
stimulus applied, and that the chemical stimulus is
more sensitive than the thermal one.
SJW as well as CHL and MET fractions produced bell-
shaped dose-response curves in both thermal and chem-
ical painful conditions. Furthermore, CHL and MET
fractions produced a bell- shaped dose-response curve
not only in the abdominal-constriction test, but also in
the hot-plate test. At present we do not have a clear ex-
planation, but it appears to be a typical trait for SJW
since even its antidepressant activity, one of the main
properties of the plant, shows a bell-shaped trend.19
The main components of the SJW dried extract are
phloroglucinols, naphtodiantrones, and flavonoids, andtheir role on the modulation of the pain threshold was
investigated. We obtained a chloroform fraction (CHL)
containing phloroglucinols, mainly represented by hyper-
forin, and a methanol fraction (MET) that was a hypericin-
and flavonoid-rich fraction. Both CHL and MET fractions
increased the licking latency values in the hot-plate test
and inhibited the acetic acid-induced abdominal constric-
tions showing a time-course profile comparable to the
dried extract. The intensity of the antinociceptive activity
of both fractions against a thermal stimulus was compara-
ble. Conversely, when a chemical nociceptive stimulus was
applied, MET was more effective than CHL. These data
indicate that all SJW main components are responsible
for the antinociceptive properties of the SJW dried ex-
tract, suggesting a prominent role of hypericin/flavonoid
against a chemical noxious stimulus.
The thermal antinociception induced by SJW dried
extract underlies the activation of the opioid system as
this analgesia is prevented by the opioid antagonist
naloxone. Phloroglucinols might be responsible for this
opioid effect since hyperforin inhibited binding to the
Figure 6. Antinociceptive profile of St. John’s Wort (SJW) and chloroform (CHL), and methanol (MET) fractions in the acetic acid-in-
duced abdominal constriction test. (A): dose-response curve for the antinociceptive effect of SJW dried extract (1–60 mg/kg po). The
number of abdominal constrictions was recorded 90 minutes after SJW administration. Vertical lines represent s.e.m.; *P < .05 in com-
parison with carboxymethylcellulose (CMC) group. (B): dose-response curve of the CHL (1–60 mg/kg po) and MET (30–60 mg/kg po)
fractions. The number of abdominal constrictions was recorded 90 minutes after CHL and METadministration. Vertical lines represent
s.e.m.; *P < .05 in comparison with carboxymethylcellulose (CMC) group. (C): comparison among MET fraction antinociception and its
main components hypericin (HYR), quercetin (QUER), hyperoside (HYS). The number of abdominal constrictions was recorded 90 min-
utes after administration. Vertical lines represent s.e.m.; *P < .05 in comparison with carboxymethylcellulose (CMC) group.
156 St John Wort’s Antinociceptionopioid receptors with higher affinity than hypericin and
flavonoids.27,28 The prevention by naloxone of CHL anti-
nociception further supports this hypothesis. The SJW
and CHL opioid antinociception is mediated by the unse-
lective stimulation of m, d and k-opioid receptor subtypes
since the k-opioid antagonist nor-NBI,18 the m-opioid
antagonist CTOP,16 the d1-opioid antagonist BNTX,26
and the d2-opioid antagonist naltriben29 were all able
to prevent SJW dried extract and CHL antinociception.Binding of [3H]naloxone to the m- and k-opioid receptor
was inhibited in the presence of SJW extract,28 support-
ing present results. CHL fraction contains phloroglucinols
together with a small amount of the flavonoid biapige-
nin. The prevention by naloxone of the CHL antinocicep-
tion indicates a major involvement of hyperforin since
biapigenin binds to opioid receptors with a much lower
affinity than hyperforin.27 The administration of purified
hyperforin produced an antinociceptive effect
Figure 8. Lack of effect of St. John’s Wort (SJW) dried extract,
chloroform (CHL), and methanol (MET) fractions on mouse spon-
taneous mobility (A), and inspection activity (B), evaluated in the
mouse hole-board test, and on mouse motor coordination eval-
uated in the mouse rota-rod test (C). Amphetamine was admin-
istered at the dose of 2 mg kg1 sc; Vertical lines represent s.e.m.
Figure 7. Mechanism of chemical antinociceptive activity of St.
John’s Wort (SJW) and fractions. (A): Lack of effect by pretreat-
ment with naloxone of SJW dried extract (30 mg kg1 po) antino-
ciception in the mouse acetic acid-induced abdominal
constriction test. The number of abdominal constrictions was re-
corded 90 minutes after SJW, chloroform (CHL), and methanol
(MET) administration. Vertical lines represent s.e.m.; *P < .05 in
comparison with control group (CMC-treated mice); xP < 0.05 in
comparison with SJW-treated animals. (B): Prevention by pre-
treatment with PMA of SJW dried extract (30 mg kg1 po) and
MET (30 mg kg1 po) antinociception in the mouse acetic acid-in-
duced abdominal constriction test. The number of abdominal
constrictions was recorded 90 minutes after SJW, CHL and MET
administration. Vertical lines represent s.e.m.; *P< .05 in compar-
ison with control group (CMC-treated mice); xP < 0.05 in compar-
ison with SJW-treated animals.
Galeotti et al 157comparable to that induced by the CHL fraction, further
suggesting the prominent role of hyperforin in the CHL
activity.
Conversely to the CHL fraction, MET fraction thermal
antinociception was unmodified by naloxone pretreat-
ment. MET fraction contains hypericins and flavonoids,
and both components might be potentially involved in
the SJW mechanism of antinociceptive action. Total
hypericins amount to about .3% of SJW dried extract,
have been isolated only in few other plants, and have
long been known to be related to many pharmacological
propertiesofSJWsuchasantidepressive, antineoplastic, an-
titumor and antiviral activities.20 Flavonoids account for
about 12% of SJW dried extract. A role of flavonoids in
the SJW-induced modulation of pain threshold might behypothesized since it has been reported that flavonoids
contribute to the anti-inflammatory effects of the plant,34
and antinociceptive properties have been reported for
the flavonoid myricitrin.24 Enzyme assays performed on
rat brain demonstrated that hypericin and pseudohypericin
are potent and selective inhibitors of the protein kinase C
(PKC).20,33 In vitro studies reported that some flavonoids in-
hibit ratbrainPKCactivity. Amongthem, quercetin isone of
the most potent.11 PKC is a family of enzymes involved in
numerous important cellular events, including pain modu-
lation. The activation of PKC has been related to the induc-
tion of a painful condition whereas PKC blockers decreased
nociception.36 Pretreatment with the PKC activator PMA,
administered at a concentration able to prevent PKC-
mediated antinociception,13 antagonized MET antinoci-
ception whereas CHL increase of pain threshold remained
unmodified, indicating that the MET effect underlies the
blockade of the PKC-mediated intracellular pathway. To
identify the MET component responsible for the increase
of pain threshold, the effect produced by administration
of purified MET fraction components was investigated.
158 St John Wort’s AntinociceptionHypericin showed antinociceptive properties of intensity
comparable to that produced by MET whereas the flavo-
noids hyperoside and quercetin neither increased the
pain threshold nor potentiated the hypericin-induced anti-
nociception. Hypericin appears, therefore, to be the most
effective component of the MET fraction.
Hypericin and hyperforin appear to be the most effec-
tive components of SJW in the induction of thermal
antinociception. However, a cumulative effect of both
components in the dried extract was not observed. We
do not havea clearexplanationfor this effect, but it should
be taken into account that, conversely to the purified ac-
tive components, in a dried extract there are many constit-
uents that, even if pharmacologically ineffective, might
positively or negatively modulate the pharmacokinetic
properties of the dried extract (ie, increasing/decreasing
absorption, bioavailability, solubility, etc.), leading to an
increased/decreased pharmacological activity.
Purified hypericin also reduced the number of abdom-
inal constrictions, a result as effective as the MET fraction.
The flavonoids hyperoside and quercetin were devoid of
any antinociceptive and/or potentating effect. These
data represent evidence for a prominent role of hypericin
in the MET-induced antinociception and also in an acute
chemical-pain condition. The PKC activator PMA pre-
vented the inhibition of acetic acid-induced abdominal
constrictions produced by SJW dried extract and MET
that, conversely, remained unmodified by naloxone
administration. SJW antinociceptive effect against
a chemical stimulus appears to be mainly related to the
PKC-blocking properties of hypericin and, conversely to
the thermal antinociception, the opioid system was only
marginally involved. This hypothesis was further sup-
ported by the higher efficacy showed by the MET fraction
in comparison with the slight reduction of the number of
abdominal constrictions produced by the CHL fraction.
The contribution of CHL is so modest that it is probably
unable to influence the effect produced by MET and, as
a consequence, naloxone did not modify the SJW-in-
duced chemical antinociception. In agreement with our
findings, recent experiments performed in the mouse for-
malin test observed that the SJW antinociception was
unaffected by naloxone.35 It should also be noted that
different mechanisms have been proposed for hyper-
forin,23 including mechanisms that might be involved in
the modulation of the pain threshold. For these reasons,
mechanisms other than the opioid cannot be excluded.SJW and its major components interact with numerous
neuronal systems able to modulate the pain threshold.
Receptor-binding and enzyme-inhibition assays carried
out using hypericum extract demonstrated significant
affinity for adenosine, GABAA, GABAB, benzodiapine,
MAOA, MAOB, and inhibitory activity towards synapto-
somal uptake of serotonin, dopamine, and noradrena-
line.2 The MAO-inhibitory properties of SJW were
mainly due to hypericin20,32 whereas the inhibition of
monoamine synaptosomal uptake is related to the pres-
ence of hyperforin.8,9,14,25 The involvement of the adren-
ergic system can be ruled out since the a´2-adrenoceptor
antagonist yohimbine did not prevent SWJ-, CHL-, and
MET-fractions-induced antinociception. A muscarinic-
mediated mechanism can also be excluded due to the
lack of antagonism by atropine.
SJW dried extract showed antinociceptive properties
after oral administration indicating that it might poten-
tially act through a central as well as a peripheral
mechanism. Furthermore, the results from the abdomi-
nal-constriction test did not ascertain the SJW site of ac-
tion. Acetic acid acts indirectly by inducing the release of
peripherally—as well as centrally—acting endogenous
mediators,4 even if it is supposed to be mediated primar-
ily via a peripheral mechanism.31 However, the antago-
nism of SJW antinociception produced by the icv
administration of PMA suggests that this effect is
centrally mediated.
SJW dried extract, CHL, and MET fractions, at the high-
est active doses employed in the present study, did not
cause any detectable modification in mouse gross behav-
ior. An altered spontaneous mobility and locomotor
activity induced by SJW administration could lead to
a misinterpretation of the results obtained. Additional
behavioral tests were performed to make sure that treat-
ments did not alter the above-mentioned parameters.
In conclusion, our findings showed that SJW, CHL, and
MET fractions produce a prolonged and tolerable
antinociception in mice in a condition of acute thermal
and chemical pain. In addition, the SJW major compo-
nents, hypericin and hyperforin, increased the pain
threshold through the selective modulation of 2 differ-
ent intracellular pathways: the presence of hypericin
was fundamental to induce both thermal and chemical
antinociception through the inhibition of the PKC activ-
ity, whereas hyperforin selectively produced a thermal
opioid antinociception.References
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